24.05.2022 - 26.05.2022Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 09:00 - 16:30
Temi della conferenza Meaningful progress in establishing causative genetic mutations and environmental factors implicated in ALS disease progression and advances in validating emerging biomarkers to evaluate treatment response has meant that the landscape for drug development in ALS is exploding. With exciting new targets, revised inclusion criteria, and opportunities to implement digital biomarkers for remote and sensitive monitoring, we have never been closer to bringing meaningful therapies to patients.
Professional congress organizer (PCO) Hanson Wade
Annotazioni Speakers: Amir Lahav, Head of Digital R and D, Digital Healthcare Innovation, Mitsubishi Tanabe Pharma Holdings America, Andrew Wolff, Senior Vice President, Senior Fellow, Clinical Research and Development, Cytokinetics and more.